Morgan Stanley analyst Vikram Malhorta maintains Paramount Group (NYSE:PGRE) with a Overweight and lowers the price target from $10 to $8.
Checkpoint Therapeutics Announces Presentation Of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing
Results support comparability of cosibelimab 800 mg every-two-week and 1200 mg every-three-week dosing regimens
Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date of January